Abstract
BackgroundRisankizumab, an interleukin-23 inhibitor, was efficacious and well tolerated in phase 2 and 3 clinical studies in patients with psoriatic disease.ObjectivesTo report long-term risankizumab safety in patients with psoriatic disease.MethodsRisankizumab...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have